The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The U.S. Food and Drug Administration accepted for priority review the license application for the use of Dupixent in adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis
Sanofi SA’s eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.
Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, while several of the company’s key drugs are selling well.
Shares of Realm Therapeutics plunged more than 50 percent after the company’s Phase II atopic dermatitis drug failed to distinguish itself from the control arm in the study.
Galapagos and MorphoSys signed an exclusive development and commercialization deal with Novartis for a drug compound being developed for the treatment of inflammatory diseases.
Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.
Regeneron Pharmaceuticals reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for its flagship eye treatment Eylea and new eczema drug Dupixent.
Roche is offloading some rights to what was once one of its top drug prospects, lebrikizumab, for payments that could total more than $1 billion after the medicine produced only lackluster results in an asthma study during 2016.